Lightbridge Corporation — Q3 2022 Form 10-Q
Reporting period: Three and nine months ended September 30, 2022. Lightbridge is a pre-revenue nuclear-fuel technology company developing metallic fuel; it remains in the research and development stage.
Financial performance and position
| Metric | Q3 2022 | Q3 2021 | Nine months 2022 | Nine months 2021 |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Operating expenses | $2.20 million | $2.20 million | $5.98 million | $6.14 million |
| Operating loss | $2.13 million | $1.91 million | $5.70 million | $5.57 million |
| Net loss | $2.04 million | $1.91 million | $5.59 million | $5.53 million |
| Basic and diluted loss per share | $0.18 | $0.31 | $0.53 | $0.92 |
- At September 30, cash and cash equivalents were $31.3 million, including $20.0 million in U.S. Treasury bills; working capital was approximately $30.4 million. Total assets were $31.7 million and stockholders’ equity was $30.5 million.
- There was no debt or line of credit. Current liabilities were $1.19 million.
- Nine-month operating cash use was $4.10 million; investing cash use was $6,174. Financing provided $10.65 million, principally from common-stock sales, resulting in a $6.54 million increase in cash.
- No meaningful revenue-based margin measure is available because the company reported no revenue.
Changes versus the prior comparable periods
- Q3 net loss increased by approximately $0.13 million year over year; nine-month net loss was broadly unchanged. Q3 operating loss widened, while nine-month operating loss increased slightly.
- Nine-month G&A rose $0.32 million to $5.38 million, primarily from stock compensation and higher director, insurance, promotion and travel costs, partly offset by lower professional fees after a 2021 arbitration settlement.
- Nine-month R&D fell $0.48 million to $0.60 million, mainly from lower consulting/outside R&D, patent, and employee costs. Contributed R&D services are presented gross as both other operating income and R&D expense; they were $0.28 million for the nine months of 2022.
- Cash increased from $24.75 million at year-end 2021, supported by $10.65 million in net proceeds from equity issuance. Common shares outstanding rose to 11.54 million from 9.76 million at year-end 2021. The company reported approximately 1.8 million shares sold under its ATM during the nine-month period.
Outlook, risks and notable items
- Management estimated average outside R&D spending of approximately $10 million annually over the next 10–15 years. It projected operating cash outflows of $1.0–$1.2 million per month and total expenditures of $12–$18 million over the next 12–15 months. Cash was expected to cover anticipated needs through Q3 2023, but actual R&D spending could exceed estimates.
- The filing states that substantial doubt exists about the company’s ability to continue as a going concern for the 12 months following filing, despite the stated near-term cash coverage. Long-term fuel development will require significant additional capital and government support. Potential sources include equity or debt financing, strategic partners and grants; availability is not assured, and equity issuance may dilute shareholders.
- Management described a fuel-development timeline of up to 15–20 years to commercialization. Risks include technical testing and commercialization, access to test reactors, partner and government funding dependence, competition, regulation, development costs and schedule uncertainty. The company may delay or reduce R&D if funding is insufficient, which could extend the timeline.
- Development updates: Lightbridge Fuel was selected for an MIT-led study of accident-tolerant fuels for light-water SMRs. A DOE-supported PNNL project to demonstrate fuel casting using depleted uranium was expected to conclude by year-end 2022; the filing reports iterative casting and analysis work. Management cited energy security and potential SMR applications, but these are forward-looking expectations, not contracted sales or assured outcomes.
- Subsequent events: approximately 41,000 ATM shares sold for about $0.2 million net proceeds after quarter-end through filing; authorized common shares increased from 13.5 million to 25 million on October 27, 2022. All outstanding warrants expired in May 2022. No material legal proceedings were reported, and disclosure controls were assessed as effective.
Investor verification priorities
- Assess cash runway against the company’s stated spending estimates, uncertain R&D commitments and going-concern disclosure.
- Track actual DOE/partner funding, PNNL project completion, irradiation-test plans and technical milestones.
- Review ATM availability and usage, the Form S-3 offering limitations, dilution, and the effect of the expanded authorized share count.
- Monitor R&D cost trends and whether reduced spending reflects timing or constrained funding; verify progress toward any commercialization timetable.